Publication details
Alogliptin po akutním koronárním syndromu u pacientů s diabetes mellitus
| Title in English | Alogliptin after acute coronary syndrome in patients with diabetes mellitus |
|---|---|
| Authors | |
| Year of publication | 2014 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapie |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | alogliptin; acute coronary syndrome; HbA; .hypoglycaemia; pancreatitis |
| Description | Diabetes mellitus type 2 (DM2) is a serious chronic disease with an increasing incidence in developed countries. About 8% of Czech population is suffering from diabetes; about 90% of them are DM2. The main aim of the treatment is the decrease of morbidity and mortality. The treatment based on lowering blood glues is not optimal yet. A possible optimal treatment is based on so called incretins. GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide, gastric inhibitory polypeptide) are the best known incretine hormones. Both of them are metabolized by the enzyme dipeptidyl peptidase 4 (DPP-4). The effect of drugs called gliptins is based on an inhibition of the enzyme dipeptidyl peptidase 4 (DPP-4). The EXAMINE study in patients with DM2 and after acute coronary syndrome randomized 5380 patients on the treatment with alogliptin or placebo; the patients were followed 40 months (median of treatment with alogliptin was 18 months). The primary endpoint (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) was in 305 patients treated with alogliptin (11.3 %) and in 316 patients treated with placebo (11.8 %), p < 0,001 for noninferiority. The HbA,, level decreased significantly after alogliptin by 0.36 %, p < 0,001. The adverse event like hypoglycaemia, pancreatitis or haemodialysis was similar in both groups. Alogliptin in patients after acute coronary syndrome and with DM2 significantly reduced HbAk, did not influence morbidity and mortality and did not increase adverse event. |